"
Aridol is designed to identify patients with active airway inflammation
such as occurs in asthma, provide information on the severity of their
disease, and help monitor the effectiveness of their current treatment. The committee
includes eminent physicians, pharmacologists , toxicologists and pharmacists
and provides independent, scientific advice on new drugs to the TGA .

reseach oxygen

au . The changes in the airways are simply detected by measuring the
amount of air a person can exhale.rambukwella@fcr.

About TOPIGEN
Privately-held, TOPIGEN is a biopharmaceutical company developing several
new classes of drugs for respiratory disorders based upon its proprietary
platform technology using novel, DNA/RNA chemistry. Dr.

TPI-ASM8 is a first-in-class, inhaled drug that combines two
oligonucleotides into a single product delivered directly to the lungs for
knock-down of cell receptors involved in the development of chronic asthma.

cause saving

J.

Dr.

TOPIGEN is a leading biopharmaceutical respiratory company with two drugs
undergoing Phase II clinical trials for the treatment of COPD (TPI-1020)
and asthma (TPI-ASM8).bio.

groups support

To find out more about Pharmaxis , go to http://www. Yet physicians currently rely upon older tests that are often
inaccurate and cumbersome to assess airway inflammation in patients with
asthma. Forward-looking statements
in this press release include statements regarding our expectations, beliefs,
hopes, goals, intentions , initiatives or strategies, including statements
regarding the potential for Aridol and Bronchitol . Securities and Exchange
Commission., a developer of anti-inflammatory respiratory products
that inhibit multiple pathways, today announced that it has been awarded two
industry accolades.
For more detailed information on TOPIGEN visit http://www., a
biopharmaceutical company specializing in innovative respiratory
therapeutics, today announced that Dr.

asthma disease

pharmaxis. All forward-looking
statements included in this press release are based upon information available
to us as of the date hereof, and we assume no obligation to update any such
forward-looking statement as a result of new information , future events or
otherwise.S. The Genesis Innovation Award and the BRIO Award, were
formally presented March 31, 2005 at the BioMedex 2005 convention in Montreal. These drugs are uniquely
focused on inhibiting multiple inflammatory pathways at the cellular site of
inflammation using a single drug product. Paul Wotton, President and Chief
Executive Officer, will be presenting at the 8th Annual BIO CEO & Investor
Conference in New York City (February 14-15, 2006), at the Waldorf Astoria
Hotel . Wotton is presenting on Wednesday, February 15th, at 11:30 AM
in the Park Avenue Suite Center/North and will be available for one-on-one
meetings during the conference.

TPI-1020 is a novel, proprietary nitric-oxide donating derivative of
budesonide.com.

obstructive cause

About Aridol
Asthma is among the top 10 most commonly cited reasons for consulting a
physician.
"It is a real honor to be recognized with not one, but two Genesis
Awards," said Dr. "TOPIGEN has come a long way in a short while."
Presented by BIOQuebec, the Genesis Awards acknowledge outstanding
achievements by companies that play a key role in the growth of Quebec's
biotech, health technology and life sciences industries.

spontaneous asthma

Canadian Biotechnology Industry Recognizes TOPIGEN
and Founder Dr.

TOPIGEN screened, evaluated and validated this small molecule
using the company's discovery expertise and demonstrated novel activity in
models of COPD. The Company's Phase II
products and research programs are uniquely focused on inhibiting multiple
inflammatory pathways at the cellular site of lung inflammation. By
topically targeting multiple affected airway receptors with its drugs, the
Company expects to improve outcomes for many patients with respiratory
diseases.

respiratory reseach

Aridol Recommended for Market Authorisation by ADEC

For more information about Pharmaxis, go to http://www.
TOPIGEN Pharmaceuticals Inc.A.

saving traveling

Its
review and subsequent recommendation follows the TGA evaluation of clinical,
pharmacological quality and safety data submitted in January 2005, and later
consultation with Pharmaxis.com. The test requires the patient to
inhale increasing doses of Aridol, which causes the airways to narrow and
contract.

Forward-Looking Statements
The statements contained in this press release that are not purely
historical are forward-looking statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended.com

Australia:
Ashley Rambukwella
Financial + Corporate Relations Pty Ltd. This pioneering
approach has shown promising preclinical results in inhibiting the underlying
inflammation associated with many pulmonary conditions such as asthma, chronic
obstructive pulmonary disease (COPD) and allergic rhinitis (AR).com

diseases disease

In Australia, about 2
million people (10 percent) have clinical symptoms of asthma and worldwide,
over 52 million people are affected.
The lung function test, Aridol , developed by Australian researchers and
Pharmaxis Ltd, will help doctors more accurately determine the severity of a
patient's disease and allow prescription of the right amount of medication. This pioneering approach has shown promising preclinical and
clinical results in inhibiting the underlying inflammation associated with
many pulmonary conditions such as asthma, COPD and allergic rhinitis .

reseach easy

Factors
that could cause or contribute to such differences include, but are not
limited to, factors discussed in the "Risk Factors and Other Uncertainties"
section of our Form 20-F lodged with the U.

TOPIGEN Wins Two Prestigious Industry Awards

About TOPIGEN

TOPIGEN is a privately held biopharmaceutical company focused on developing
new classes of inhaled drugs for respiratory disorders.

money saving

Founded in 1998, Pharmaxis was listed on the Australian Stock Exchange in
November 2003 (symbol PXS), and on NASDAQ (symbol PXSL) in August 2005. We can not guarantee that any product candidate will receive FDA
or other regulatory approval or that we will seek any such approval. With more than 250
innovative companies as members, BIOQuebec is committed to supporting the
growth and vitality of Quebec's biotechnology industry.topigen.

For more information about BIO CEO visit
http://ceo.

medication support

The concept that has become Aridol was originally conceived by
scientists at a Sydney hospital and today's decision represents over ten years
of investment by very many people.
ADEC is appointed by the Federal Minister for Health and Ageing to advise
on the suitability of drugs for marketing in Australia.

oxygen money

CONTACT:

Alan Robertson - Chief Executive Officer
Tel: +61-2-9454-7202
Fax: +61-2-9451-3622

Released through:

United States:
Brandon Lewis
Trout Group
Tel: +1-212-477-9007
Email: blewis@troutgroup .
"Years of academic and clinical research have come together to become
TOPIGEN Pharmaceuticals ," said Dr.

PRESS RELEASE TOPIGEN's CEO to Present at BIO CEO +amp; Investor Conference

TOPIGEN's pipeline
includes small molecule and RNA-based therapeutics.

reseach disorders

Currently there is no registered , objective test in Australia to confirm the
presence or absence of lung inflammation. Wotton, President and Chief Executive Officer at
TOPIGEN.

cause money

About Pharmaxis
Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company
involved in the research, development and commercialization of therapeutic
products for chronic respiratory and autoimmune diseases. Paolo Renzi for Outstanding Scientific Contributions

MONTREAL, and RANDOLPH, N., TOPIGEN
Pharmaceuticals Inc. In October 2005, TOPIGEN in-licensed North American rights
for the compound from NicOx S.

saving disorders

The smaller the dose required to cause
contraction, the more severe the patient's asthma. By topically targeting multiple
affected airway receptors with its drugs, the company expects to improve
outcomes for many patients with respiratory diseases. For
more detailed information on TOPIGEN visit www.

obstructive pneumothorax

Asthma is a widespread and chronic
condition which has a major impact on public health. Its development
pipeline of products include Aridol(TM) for the management of asthma,
Bronchitol(TM) for cystic fibrosis and chronic obstructive pulmonary disease
(COPD) and PXS64 for the treatment of multiple sclerosis. The
company is headquartered in Sydney at its TGA-approved manufacturing
facilities .
The simple 15 minute test uses a patented formulation of mannitol
manufactured into a respirable dry powder.com. I would like to thank everyone associated with TOPIGEN,
from our shareholders to our outstanding team of employees for making all of
this possible.
In November 2004, TOPIGEN closed a USD$20 million Series B round in Canada
with venture investors.topigen., for COPD and other respiratory diseases
with an option for worldwide rights.

obstructive conditions

"Our unique approach of developing products that inhibit
multiple inflammatory pathways involved in complex respiratory diseases may
improve the lives of millions of patients suffering from debilitating
conditions like asthma, COPD and allergic rhinitis," he added.
TOPIGEN's lead product for asthma, ASM8, is currently undergoing human
Phase 1 clinical studies.

active lung

Aridol will soon be available to physicians and respiratory labs treating
patients with asthma and it holds out the prospect for better disease
outcomes.au

These awards
highlight the Company's remarkable capacity for scientific innovation and
business leadership .topigen. Wotton's presentation will be webcast and available, both live and for
replay, via the Company 's website at www.com.

disorders spontaneous

We look forward to the next phase in the
development of Aridol.au
or contact Jane Sugden, Investor Relations +61 2 9454 7230.
Doctors can use the results of this test to measure the severity of a
patient's asthma allowing better control of the disease.
Tel: +61-2-8264-1004 or +61-407-231-282
Email: a.
The BRIO Award is a very distinctive honor since it is given to an
individual who has made significant contributions to both improving medical
care and advancing the life sciences industry.
This pioneering approach addresses the issue of pathway redundancy by
blocking the expression of specific genes in multiple pathways responsible
for asthma and allergic inflammation.

breathers money

Paul K.

saving asthma

Alan Robertson, Pharmaxis chief executive officer said: "The positive
opinion on Aridol from ADEC is great news for people living with asthma.

easy active

People without airway
inflammation do not respond to an Aridol challenge test. Paolo Renzi, Founder and Chief Scientific
Officer of TOPIGEN. The Company believes that ASM8 has the potential to
replace steroids in the treatment of asthma and may provide patients with a
convenient once-a-day topical dosing regimen and an improved side-effect
profile over other medications currently available.jsp

obstructive saving

SYDNEY, Australia, Specialist
pharmaceutical company Pharmaxis Ltd (ASX: PXS; Nasdaq: PXSL) announced today
that the Australian Drug Evaluation Committee (ADEC) has recommended to the
Therapeutic Goods Administration (TGA) that its first product, Aridol(TM), be
registered for sale in Australia.pharmaxis.com.

The 8th Annual BIO CEO & Investor Conference, one of the year's largest
life science investor events, provides a forum for private and public
companies to present progress on their development programs with investors
and the financial community. The presentation will include an update of the
company's progress on the two programs.org/opencms/ceo/2006/index.